drug
Wegovy Pill
Marketedupdated 5mo agoby Novo Nordisk Inc
Approvedannual revenue · 2024–2024peak $8.4B
community read0 votes
🐶 often sniffed alongside
top 8- drugOzempic168 co-mentions · 74 sources
- drugWegovy168 co-mentions · 74 sources
- tagApproval124 co-mentions · 44 sources
- drugRybelsus94 co-mentions · 72 sources
- drugsemaglutide94 co-mentions · 72 sources
- tagRecall33 co-mentions · 27 sources
- companyNovo Nordisk Inc22 co-mentions · 3 sources
- tagSmall Molecule22 co-mentions · 18 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.
indications
investigational
Obesity
all catalysts(2)
Trials studying Wegovy Pill
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
- —Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
- phase4Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
- phase3A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- phase1A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
- phase3A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- phase3A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
- phase2A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 8, 2027
153 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (165)
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Oct 10, 2038method-of-use (U-4418)US 12029779
- Oct 10, 2038method-of-use (U-3162)US 12029779
- Oct 10, 2038method-of-use (U-2628)US 12295988
- Oct 10, 2038method-of-use (U-4418)US 12551536
- Oct 10, 2038method-of-use (U-4418)US 12551536
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- Jun 21, 2033formulationUS 10335462
- Jun 21, 2033method-of-use (U-2580)US 10335462
- Jun 21, 2033method-of-use (U-2580)US 10335462
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-4418)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759503
- Mar 15, 2033formulationUS 11759503
- Mar 15, 2033formulationUS 11759503
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031compositionUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
FDA exclusivities (29)
- Dec 22, 2028NPNP2.2y
- Dec 22, 2028NPNP2.2y
- Dec 22, 2028NPNP2.2y
- Dec 22, 2028NPNP2.2y
- Oct 17, 2028I-976Indication (3y)2.0y
- Oct 17, 2028I-976Indication (3y)2.0y
- Oct 17, 2028I-976Indication (3y)2.0y
- Oct 17, 2028I-976Indication (3y)2.0y
- Oct 17, 2028I-976Indication (3y)2.0y
- Oct 17, 2028I-976Indication (3y)2.0y
- Aug 15, 2028I-973Indication (3y)1.9y
- Aug 15, 2028I-973Indication (3y)1.9y
- Aug 15, 2028I-973Indication (3y)1.9y
- Aug 15, 2028I-973Indication (3y)1.9y
- Aug 15, 2028I-973Indication (3y)1.9y
- Jan 28, 2028I-961Indication (3y)1.3y
- Jan 28, 2028I-961Indication (3y)1.3y
- Jan 28, 2028I-961Indication (3y)1.3y
- Jan 28, 2028I-961Indication (3y)1.3y
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Mar 8, 2027I-935Indication (3y)153d
- Jul 21, 2026D-190New Indication (3y)
News(10)
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 3d ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 4d ago
- Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse eventsPatients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.biospace · 4d ago
- #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapyMILAN — Regeneron’s investigational drug helped obesity patients who stopped taking Novo’s Wegovy regain a similar amount of muscle mass to what they lost when they took the GLP-1, according to new…endpoints · 4d ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&DSanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.fiercebiotech · 4d ago
- Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…biospace · 5d ago
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetesMILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination del…endpoints · 5d ago
- Lilly builds commercial case for GLP-1 products over Novo with indirect analysesEli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…biospace · 5d ago
- Lilly raises diabetes weight-loss bar with amylin-Zepbound comboEli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…fiercebiotech · 5d ago
- Novo to pay Hengrui up to $2.6B for a once-weekly obesity pillThe deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.biopharma_dive · 6d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that